Attached files
| file | filename |
|---|---|
| 10-Q/A - FORM 10-Q/A - Travere Therapeutics, Inc. | d102019d10qa.htm |
| EX-31.2 - EX-31.2 - Travere Therapeutics, Inc. | d102019dex312.htm |
| EX-32.1 - EX-32.1 - Travere Therapeutics, Inc. | d102019dex321.htm |
| EX-10.1 - EX-10.1 - Travere Therapeutics, Inc. | d102019dex101.htm |
| EX-31.1 - EX-31.1 - Travere Therapeutics, Inc. | d102019dex311.htm |
Exhibit 32.2
CERTIFICATION OF
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Amendment No. 1 on Form 10-Q/A of Retrophin, Inc. (the “Company”), for the period ending September 30, 2015 (the “Report”), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 22, 2015
| /s/ Laura Clague |
| Laura Clague |
| Chief Financial Officer |
| (Principal Financial Officer) |